Solid iodophor

By mixing molecular iodine with cyclodextrin and iodine ion sources at a specific temperature, a stable solid iodine complex is formed, which solves the problems of poor solubility and irritability of iodine, achieving efficient antimicrobial effects and stable water dissolution , suitable for a variety of purposes.

CN119095884APending Publication Date: 2024-12-06MEDIVIS SRL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380036029.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-29
Filing Date
2023-04-28
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art is difficult to prepare stable and efficient water-soluble iodine-based drugs, with poor solubility and irritation of iodine affecting its use in medical applications, especially during mucosal treatment.

Method used

Stable solid iodine preparation is achieved by mixing molecular iodine with a source of cyclodextrin and iodine ion and heating at a specific temperature to form a solid iodine complex CD/Ix, where x=2 or 3.

Benefits of technology

A stable solid iodine complex has high iodine content and good stability, can effectively antiviral, antibacterial and antifungal, and has high solubility in water, and is suitable for a variety of medical and agricultural uses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005099625370000071
    Figure BDA0005099625370000071
  • Figure BDA0005099625370000072
    Figure BDA0005099625370000072
  • Figure BDA0005099625370000081
    Figure BDA0005099625370000081
Patent Text Reader

Abstract

The present invention describes novel iodo-complexes and novel methods for obtaining them.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Iodine is an element used in the chemical industry and particularly in the pharmaceutical industry because it has biocidal properties (antibacterial, antiviral and antifungal). Iodine has several disadvantages because it is insoluble in water, its crystals sublimate at room temperature, and the vapor has oxidizing and chemical corrosiveness. Therefore, it is difficult to store, handle and be soluble in water, which is a necessary requirement for obtaining aqueous preparations of iodine-based drugs. The poor solubility of iodine can be overcome by dissolving it in ethanol, but alcohol iodine solution has disadvantages, particularly in tolerance, irritation and toxicity, particularly when treating the mucous membranes of various organs. By adding iodine ions to iodine solution to obtain triiodide (I3 - ) can reduce these problems. However, even in this case, the irritating effects are not completely eliminated. Despite these disadvantages, Lugol's aqueous and alcoholic iodine solutions containing 5% iodine and 10% potassium iodide, known as iodine tinctures, have been described in several pharmacopoeias for more than a century and are still in use today. In the last century, several iodine-based preparations have been developed with the aim of maintaining biocidal efficacy while reducing side effects. One of the best results was achieved with polyvinylpyrrolidone-iodide (PVP-iodine), which is the most important commercial product today. One of the advantages of this product is that it is a powdered solid with an iodine content of about 10% that is stable over time. The literature contains many patents and scientific papers discussing the use and properties of inclusion complexes between cyclodextrins (CD) and iodine (I2) in aqueous solutions. In fact, cyclodextrins are able to solubilize hydrophobic molecules in water, especially in steric and energetic situations, among which is iodine. J. Chem. Educ. vol. 71, no. 8, 1 August 1994 pp 708-714 describes how to solubilize iodine in water using β-cyclodextrin (βCD). Solutions of iodine in water obtained by forming a βCD / I2 complex are now used as mouthwash for rinsing the mouth and are commercially available in Japan.

[0002] Another paper (Drug Development and Industrial Pharmacy Vol. 28, No. 10, pp. 1303-1309, (2002)) reports hydroxypropyl-α-cyclodextrin (HPαCD) as a better alternative to α-cyclodextrin (αCD) for forming complexes with iodine, being 100 times more soluble relative to αCD and also relative to β-cyclodextrin (βCD); moreover, it has a higher preservative activity than the world's most used iodine-based product 1 PVP-iodine. In the same paper, the greater stability of the HPαCD / iodine complex is mentioned; in fact, it is reported that the loss of iodine in aqueous solutions in which hydroxypropyl-α-cyclodextrin is present is lower than in aqueous solutions of iodine in which α-cyclodextrin or β-cyclodextrin is used, and is also lower than in aqueous solutions in which PVP or KI is present as complexing agent. JP No S51100892A describes the preparation of solid complexes βCD / I2 by precipitation utilizing the poor solubility in water that these cyclodextrin / iodine complexes already have at room temperature, which can be used as antifungal preservatives and food preservatives.

[0003] Chinese patent application CN 107517963A reports the preparation of the complex HPαCD / I2 from an aqueous solution by precipitation in the presence of a Tween 80 surfactant. This cyclodextrin is more soluble than the respective native αCD and therefore requires a temperature of 0°C to precipitate it as a complex with iodine. The procedure involves the presence of potassium iodide in the aqueous solution, not exceeding 30% of molecular iodine. Even at refrigerated temperatures, the preparation process by precipitation from a saturated solution as implemented for HPαCD becomes impossible, for all very soluble substituted β-cyclodextrins, such as hydroxypropyl-β-cyclodextrin, and likewise for all γ-cyclodextrins and all cyclodextrins substituted with groups that confer great solubility in water. As mentioned above, for cyclodextrins such as hydroxypropyl-β-cyclodextrin (HPβCD), methyl-β-cyclodextrin (RMβCD) and sulfobutyl ether-β-cyclodextrin (SBEβCD), it is impossible to obtain a solid complex CD / I2 in powder form. It is even more difficult for hydroxypropyl-γ-cyclodextrin (HPγCD), methyl-γ-cyclodextrin, sulfobutyl ether-γ-cyclodextrin and methyl-carboxyl-thioether-γ-cyclodextrin (sugammadex sodium); in fact, with the exception of methyl-β-cyclodextrin (RMβCD), the existence and preparation of these cyclodextrins as solid complexes have not been reported. The paper by Tze-Loon reports the preparation of the solid complex RMβCD / I2 by treating RMβCD with an excess of iodine in a rotary evaporator; the formation of the complex is thus obtained by inclusion in the cavity of methyl-β-cyclodextrin of gaseous iodine obtained by heating at high temperatures. This preparation leads to the formation of the complex RMβCD / I2, a procedure of which is only of academic interest and is not easily implemented from an industrial point of view, as is the case with precipitation (RMβCD is too soluble for precipitation methods).

[0004] In summary, the preparation of solid CD / I2 complexes reported in the scientific and patent literature is essentially limited to those few complexes that are most capable of forming saturated solutions and thus precipitating. Summary of the invention

[0005] The inventors of the present patent application surprisingly developed a new method for preparing solid iodophors comprising cyclodextrins. BRIEF DESCRIPTION OF THE DRAWINGS

[0006] Figure 1 shows the thermogram associated with HPβCD used in the preparation of iodophors, and Figure 2 The relevant FTIR graph is shown in Figure 2.

[0007] Figure 3 shows the thermal analysis diagram associated with HPβCD / I3K of Example 3, and Figure 4 The relevant FTIR graph is shown in Figure 2.

[0008] Figure 5 shows the thermal analysis diagram associated with HPβCD / I3K of Example 4, and Figure 6 The relevant FTIR graph is shown in Figure 2.

[0009] Figure 7 shows the thermogram associated with RMβCD used in the preparation of iodophors, and Figure 8 The relevant FTIR graph is shown in Figure 2.

[0010] Fig. 9 shows the thermogram associated with RMβCD / I3H of Example 6, and Fig.10 The relevant FTIR graph is shown in Figure 2.

[0011] Fig.11 shows a thermogram associated with αCD used in the preparation of iodophors, and Fig.12 The relevant FTIR graph is shown in Figure 2.

[0012] Fig.13 shows the thermal analysis diagram associated with αCD / I3H of Example 10, and Fig.14 The relevant FTIR graph is shown in Figure 2.

[0013] Purpose of the Invention

[0014] In a first object, a process for preparing solid complexes comprising iodine, known as "iodophors", is described.

[0015] In a second object, solid complexes comprising iodine (called "iodophors") obtained with the process of the invention and solid complexes comprising iodine (called "iodophors") thus obtained are described.

[0016] In a third object, formulations comprising the complexes of the invention are described.

[0017] In a fourth object, complexes and preparations comprising the complexes of the invention for medical and veterinary use are described.

[0018] In particular, complexes and formulations comprising the complexes of the invention are described for antiviral, antibacterial and antifungal medical uses.

[0019] In a further object, the use of the solid complexes of the invention and formulations comprising them as antiviral, antibacterial and antifungal agents is described.

[0020] In a still further object, the use of the solid complexes of the invention and preparations comprising them in agriculture, in the field of phytosanitary measures, in aquaculture and in animal husbandry is described.

[0021] Specific embodiments of the invention

[0022] definition

[0023] For the purpose of this patent application, the following terms are defined:

[0024] Available iodine = iodine that can be titrated with thiosulfate

[0025] Total iodine = iodide ion + titratable iodine

[0026] Free iodine = uncomplexed iodine which can be determined in dialysis tests or in electrochemical models or which can be extracted from an aqueous solution of defined concentration using heptane or cyclohexane.

[0027] In the continuation of this patent application, the compounds described will be referred to by the term "iodophor".

[0028] In a first object, a process for preparing the complexes of the invention is described.

[0029] In particular, such a method comprises the steps of mixing molecular iodine with a source of iodide ions and adding cyclodextrin (Method A).

[0030] Likewise, such a method may include the step of merely mixing molecular iodine with the cyclodextrin (Method A').

[0031] Alternatively, the method may comprise mixing the cyclodextrin with a source of iodide ions to obtain CD / I - A first step of complexation and a second step of addition of molecular iodine (Method B1).

[0032] In particular, the second step may include heating the CD / I in a sealed heating container at a temperature of about 40-120°C. - and molecular iodine for several hours until a solid iodine complex CD / I3 is obtained. - .

[0033] Likewise, the method may comprise a first step of mixing cyclodextrin with molecular iodine to obtain a CD / I2 complex and a second step of adding an iodide ion source (Method B2).

[0034] Thus, in the above methods B1 and B2, there is a first step in which one of molecular iodine and a source of iodide ions is added to the cyclodextrin, and then the other (of molecular iodine and a source of iodide ions) is added; thus, in this method, molecular iodine and a source of iodide ions are added to the cyclodextrin separately.

[0035] For the purpose of the present invention, in the method, the cyclodextrin is preferably selected from the group comprising substituted cyclodextrins and unsubstituted cyclodextrins or unsubstituted α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin.

[0036] Examples of cyclodextrins are thus: α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin, hydroxypropyl-α-cyclodextrin (HPαCD), methyl-β-cyclodextrin (RM-β-CD), sulfobutyl ether-β-cyclodextrin (SBEβCD), hydroxypropyl-γ-cyclodextrin (HPγCD), methyl-γ-cyclodextrin, sulfobutyl ether-γ-cyclodextrin, methyl-carboxy-thioether-γ-cyclodextrin (sugammadex sodium).

[0037] As for the source of iodide ions, it can be:

[0038] - an iodide salt, for example an iodide of an alkali metal or alkaline earth metal; for example, it may be potassium iodide, or

[0039] -Hydroiodic acid (HI).

[0040] According to one aspect of the present invention, hydroiodic acid can be formed in situ from an iodine salt and a reducing agent.

[0041] In particular, such a reducing agent may be an acid selected from the group comprising carbonic acid, formic acid, oxalic acid or ammonium salts thereof; alternatively, urea may be used.

[0042] According to one aspect of the present invention, the mixing of the components can be carried out in a dry manner.

[0043] In particular, such mixing can be obtained in a rotary or vibrating ball mill or in a mortar with a pestle; alternatively, equipment capable of comminuting, crushing, grinding or micronizing can be employed.

[0044] In a particular aspect of the invention, the drying process may be facilitated using LAG (Liquid Assisted Grinding) technology, soaking the solid mixture with a solvent in an amount of about 0.1-1.2 ml / g of solid mixture.

[0045] The amounts of the above solvents are minimal and insufficient to obtain a solution.

[0046] In particular, such solvent is selected from the group comprising: water, water-alcohol mixtures, ethanol, isopropanol, tetrahydrofuran, diethyl ether, ethyl acetate, hexane.

[0047] This process can be carried out by heating the mixture at a temperature of about 40-120°C for several hours in a sealed heating container until a solid iodine phorbium complex CD / I3 is obtained. - To carry out.

[0048] According to another aspect of the present invention, the mixing of the components may be carried out in a solvent.

[0049] In particular, such solvent is selected from the group comprising: water, water-alcohol mixtures, ethanol, isopropanol, tetrahydrofuran, diethyl ether, ethyl acetate, hexane.

[0050] For the purposes of the present invention, the molar ratio of cyclodextrin, molecular iodine and iodide ion in the mixture placed under mechanical stirring is preferably from about 1:0.05 to about 1:2 mol / mol of cyclodextrin and molecular iodine, and preferably the ratio is between about 1:0.25 and about 1:1.2.

[0051] The molar ratio of molecular iodine to iodide ion (eg, introduced as an iodine salt or as hydroiodic acid) may range from about 1:0 to about 1:4 mol / mol, and preferably the ratio is between about 1:0.25 and about 1:2.

[0052] If the iodide ion is generated in situ by reaction of iodine with an organic acid, the molar ratio may be as follows:

[0053] - the ratio of cyclodextrin to iodine is preferably about 1:0.1 to about 1:4, and

[0054] - The ratio of iodine to organic acid or its ammonium salt or amide is from about 1:0.2 to about 1:0.8.

[0055] The method of the present invention produces the preparation of solid iodophor.

[0056] According to one aspect of the present invention, such iodophor may be subjected to a further grinding and / or micronization step until the desired particle size is obtained.

[0057] According to a second object of the invention, a solid complex (iodophor) is described, obtained by the described process, having the formula:

[0058] CD / I x ,

[0059] in

[0060] CD = cyclodextrin and

[0061] x=2 or 3.

[0062] When x=2, it refers to a molecular iodine complex (I2).

[0063] When x=3, it refers to the triiodide ion complex (I3 - ).

[0064] According to a first aspect, the solid iodine phorbium complex of the present invention has the formula CD / Ix, wherein x=2; thus, such complex has the formula CD / I2.

[0065] In a second aspect of the present invention, the solid iodophor complex of the present invention has the formula CD / Ix, wherein x=3; thus, such a complex has the formula CD / I3-.

[0066] In one aspect of the present invention, the above-mentioned solid iodine phorbium complex is obtained by the method of the present invention.

[0067] For the purpose of this patent application, the solid iodophor complex is presented using a particle size measurement method that depends on the conditions applied in the process and in particular in the milling step.

[0068] The solid iodine complex described in this patent application includes:

[0069]

[0070] In one aspect of the invention, the solid iodine complexes reported in the above table are obtained by the method of the present invention:

[0071]

[0072]

[0073] According to certain aspects, thus, complexes comprising cyclodextrins (or "iodophors") are described.

[0074] In particular, such complexes have the formula:

[0075] CD / I x ,

[0076] in

[0077] CD = cyclodextrin and

[0078] x=2 or 3.

[0079] When x=2, it refers to a molecular iodine complex (I2).

[0080] When x=3, it refers to the triiodide ion complex (I3 - ).

[0081] In a preferred aspect, the CD is a cyclodextrin selected from the group consisting of substituted cyclodextrins and unsubstituted cyclodextrins or unsubstituted α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin.

[0082] Examples of cyclodextrins are thus: α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin, hydroxypropyl-α-cyclodextrin (HPαCD), methyl-β-cyclodextrin (RM-β-CD), sulfobutyl ether-β-cyclodextrin (SBEβCD), hydroxypropyl-γ-cyclodextrin (HPγCD), methyl-γ-cyclodextrin, sulfobutyl ether-γ-cyclodextrin, methyl-carboxy-thioether-γ-cyclodextrin (sugammadex sodium).

[0083] For the purpose of this patent application, in the compound having the above formula, when x=2, CD is not: α-cyclodextrin (α-CD), β-cyclodextrin (β-CD), hydroxypropyl-α-cyclodextrin (HPαCD), methyl-β-cyclodextrin (RM-β-CD).

[0084] According to a third object, there is a preparation comprising the solid iodine phorbium complex of the present invention.

[0085] In particular, such formulations include the solid iodine phorbium complexes CD / I3 and CD / I2 of the present invention.

[0086] More particularly, the formulation of the invention comprises a solid iodine phorbium complex in a concentration such that a solution containing between 0.01 and 2% available iodine (titrable with thiosulfate) is obtained (corresponding to an iodine phorbium concentration range of about 0.1 to 30%).

[0087] In particular, there may be prepared formulations in the form of solutions, gels, hydrogels, emulsions, ointments, tablets or powders.

[0088] For the purposes of the present invention, an emulsion comprises, for example, an oil phase in water, a surfactant and / or an emulsifier.

[0089] Oils that can be used for this purpose include petrolatum, mineral oil, liquid waxes, long chain esters, lanolin, liquid paraffin, essential oils, vegetable oils, hydrogenated vegetable oils, and long and medium chain triglycerides, natural or synthetic mono-, di-, and triglycerides.

[0090] The formulations may contain organic and inorganic pH buffers which may impart a pH between 2.0 and 7.0, and preferably between 3.0 and 5.5.

[0091] In a preferred aspect, the buffer is citrate buffer or phosphate buffer.

[0092] Depending on the type of formulation, one or more other components selected from the group consisting of penetrants, surfactants, emulsifiers, oils, viscosity-increasing or gelling polymers, preservatives, cyclodextrins, complexing agents, inorganic salts and mixtures of these excipients may be included.

[0093] Examples of solutions according to the invention comprising iodophor complexes are reported in the following table:

[0094] Table 5.

[0095]

[0096]

[0097] * RMβCD, HPβCD, βCD, SBEβCD, HPαCD, αCD, HPγCD Examples of ointments and creams comprising iodophor complexes according to the invention are reported in the following table:

[0098] Table 6.

[0099]

[0100] * RMβCD, HPβCD, βCD, SBEβCD, HPαCD, αCD, HPγCD Examples of emulsions according to the invention comprising iodophor complexes are reported in the following table:

[0101] Table 7.

[0102]

[0103]

[0104] *RMβCD,HPβCD,βCD,SBEβCD,HPαCD,αCD,HPγCD

[0105] According to a fourth object, complexes and preparations comprising the complexes of the invention for medical or veterinary use are described.

[0106] According to a particular aspect, the complexes and preparations comprising the complexes of the invention are described for biocidal medical or veterinary use.

[0107] More particularly, such biocidal medical or veterinary uses are antiviral, antibacterial and antifungal uses.

[0108] For the purposes of the present invention, the term "biocidal" refers to activity against a broad spectrum of viruses, bacteria, fungi, spores, mycobacteria, parasites, prions and other microorganisms.

[0109] As for viruses that infect animals, especially mammals or humans, by way of illustration, these viruses may include: papovaviruses, Lewis encephalitis viruses, retroviruses, rhabdoviruses, coronaviruses, rhinoviruses, orthomyxoviruses, caliciviruses, filoviruses, astroviruses, and probably all viruses are susceptible to the composition of the invention. Viruses such as influenza, especially H5N1 influenza, herpes simplex viruses (HSV1 and HSV2), Coxsackie viruses, human immunodeficiency viruses (I and II), Andes viruses, dengue viruses, papilloma, Epstein-Barr viruses, smallpox and other pox viruses, West Nile viruses are relevant targets for the composition according to the invention.

[0110] With respect to bacteria, these include: Gram-negative, Gram-positive, and include antibiotic-resistant ones, including: MRSA, S. aureus; S. epidermidis; S. saphrophyticus and other bacteria that cause infections in humans and animals.

[0111] With respect to fungi, these include: Aspergillus, Coccidioides, Histoplasma capsulatum, and Candida.

[0112] The solid iodophor complex of the present invention can also be used to eliminate spores, such as sporangiospores and zygospores from fungi, ascospores from ascomycetes, basidiospores from basidiomycetes, spring spores, winter spores and summer spores (uredeiospore) from fungi; also including melospores, microspores, megaspores, mitotic spores, zoospores, nonospores, spores, spores and statismospores.

[0113] In a further object, the use of the solid iodine phorbium complexes of the present invention and formulations comprising them as antiviral, antibacterial and antifungal agents is described, as described above.

[0114] Furthermore, the use of the solid iodine phorbium complexes of the invention for removing mold from surfaces where mold may infest is described.

[0115] With regard to molds, these include: Zygomicota and Ascomicota, Acrenomium, Alternaria, Aspergillus, Cladosporium, Fusarium, Mucor, Pennicillinum, Rhizopus, Trichoderma, and Stachibotrys.

[0116] For the purposes of the present invention, the treated surface may be natural or artificial.

[0117] In a still further object, the use of the solid complexes of the invention and preparations comprising them in agriculture, in the field of plant quarantine, in aquaculture and in animal husbandry is disclosed.

[0118] In particular, in agriculture, the solid iodophor complexes of the present invention find use as bioaugmentants.

[0119] In particular, in the field of plant quarantine, the solid iodophor complexes of the present invention find use as antiviral agents.

[0120] In fact, the solid iodophor complexes of the present invention can be used to combat viruses in plants.

[0121] In particular, these may be plants which are used in agriculture but also for food purposes.

[0122] The target virus can be selected from the group consisting of Partitivirus, Potyvirus, Bromovirus, Comovirus, Geminivirus, Rhabdovirus, Reovirus, SatelliteVirus, Tobaccovirus, Sequivirus, and other viruses that infect plants.

[0123] In particular, in aquaculture, the solid iodophor complex of the present invention can be used as a preservative.

[0124] In particular, in animal husbandry, the solid iodophor complex of the present invention can be used as a source of iodine.

[0125] Preparation Example

[0126] HPγCD / I3K, HPγCD / I3H, HPβCD / I3K, HPβCD / I3H, HPβCD / I 2、 Preparation examples of RMβCD / I3H, RMβCD / I3K, βCD / I3K, βCD / I3H, and αCD / I3H.

[0127] Example 1. Preparation of HPγCD / I3K

[0128] Hydroxypropyl-γ-cyclodextrin (154 g; 0.1 mol) and potassium iodide (12.5 g; 0.075 mol) were dry mixed with molecular iodine (19.0 g; 0.075 mol) and then introduced into a rotary ball mill. The mill was placed under mechanical action until the desired particle size was obtained, according to the set power, and at the end of the grinding the product was forced through a 0.038 mm sieve and then formulated. The percentage of available iodine (titrable with thiosulfate) was found to be 10.1%.

[0129] Example 1.1 Preparation of HPγCD / I3K

[0130] Hydroxypropyl-γ-cyclodextrin (154 g; 0.1 mol) and potassium iodide (12.5 g; 0.075 mol) were dry mixed and then introduced into a rotary ball mill. Depending on the power setting, the mill was placed under mechanical action until a homogeneous mixture was obtained, to which molecular iodine (19.0 g; 0.075 mol) was then added in a second stage. The iodine-containing mixture was sealed in a screw-capped glass bottle and then heated at 60° C. for 6 h. The product thus obtained was forced through a 0.038 mm sieve after cooling and then formulated. The percentage of available iodine (titrable with thiosulfate) was found to be 9.9%.

[0131] Example 2. Preparation of HPγCD / I3H

[0132] A 57% aqueous solution of 20.2 g of hydroiodic acid (equivalent to 11.5 g; 0.09 mol of hydroiodic acid) is introduced into 10 ml of ethanol, in which 22.8 g (0.09 mol) of iodine have previously been suspended. The ethanol solution thus composed is poured onto 154 g (0.1 mol) of hydroxypropyl-γ-cyclodextrin and then homogenized in a mortar with a pestle until it is dry. The almost dry powdered product is introduced into a rotary mill with a 250 ml Teflon container. The rotor acceleration is 1 g, and the rotation speed of the container is set to 180 rpm. 20 mm zirconium oxide balls are used as grinding bodies. The mechanical process lasts for 30 minutes. The percentage of available iodine in the produced iodophor is obtained to be 11.8%. The obtained powder is forced through a 0.022 mm sieve and then formulated.

[0133] Example 3. Preparation of HPβCD / I3K

[0134] 12.7g iodine (0.05mol) and 8.3g potassium iodide (0.05mol) are dissolved in 50ml ethanol, and then the ethanol solution is poured into 100g hydroxypropyl-β-cyclodextrin (0.067mol) placed in a porcelain mortar. The mixture is squeezed and homogenized with a pestle until a homogeneous paste is obtained. Ethanol is evaporated from the product for 2h at room temperature, and then pulverized with a pestle until a powder is obtained. The percentage of available iodine in the produced iodophor is obtained to be 10.1%.

[0135] Example 3.1 Preparation of HPβCD / I3K

[0136] 8.3g potassium iodide (0.05mol) is dissolved in 40ml ethanol, and then the ethanol solution is poured into 100g hydroxypropyl-β-cyclodextrin (0.067mol) placed in a porcelain mortar. The mixture is squeezed and homogenized with a pestle until a homogeneous paste is obtained. Ethanol is evaporated from the product at 50°C for 2h, and then pulverized with a pestle until a powder is obtained, to which 12.7g of previously pulverized iodine (0.05mol) is added. The iodine-containing mixture is placed in a sealed glass vial with a screw cap and heated at 60°C for 8h. The percentage of available iodine in the iodophor thus obtained is obtained to be 10.3%.

[0137] Example 3.2 Preparation of HPβCD / I3K

[0138] 12.7g iodine (0.05mol) is mixed with 100g hydroxypropyl-β-cyclodextrin (0.067mol) placed in a sealed glass container with a lid, and heated at 70°C for 6h. 8.3g potassium iodide (0.05mol) is added to the cyclodextrin iodine complex thus obtained, and then 35ml ethanol is added. The ethanol mixture thus obtained is squeezed and homogenized with a pestle until a homogeneous paste is obtained. Ethanol is evaporated from the product for 2h at room temperature, and then pulverized with a pestle until a powder is obtained. The percentage of available iodine in the produced iodophor is obtained to be 10.3%.

[0139] Example 4. Preparation of HPβCD / I3H

[0140] 15.2g iodine (0.06mol) and 13.5g of 57% hydroiodic acid aqueous solution (equivalent to 7.7g; 0.06mol hydroiodic acid) are dissolved in 30ml ethanol, and then the ethanol solution is poured into 100g hydroxypropyl-β-cyclodextrin (0.067mol) placed in a porcelain mortar. The paste is manually squeezed and homogenized with a pestle until a powder is obtained. The product is placed in air for 2h or dried again under vacuum in a rotary evaporator, and then reduced to powder with a pestle. The percentage of available iodine in the iodine tin product obtained is 12.0%. The product is prepared by the product above.

[0141] Example 4.1 Preparation of HPβCD / I3H

[0142] Hydroxypropyl-β-cyclodextrin (100 g; 0.067 mol) is suspended in 20 ml of water. To this solution is added formic acid (1.5 g; 0.033 mol) and the solution is then adjusted to pH 7.5 with ammonia solution. Iodine (25.4 g; 0.1 mol) is introduced into the suspension. The solution is placed under mechanical stirring for about 2 hours until the foaming produced by the development of CO2 ends, after which the solution is heated to 65° C. and allowed to evaporate until a pasty solid is obtained, which is mechanically treated with a pestle until a dry powder is obtained. The percentage of available iodine in the iodophor obtained is found to be 12.1%.

[0143] Example 4.2 Preparation of HPβCD / I3H

[0144] Ammonium formate (2.08 g; 0.033 mol) was dissolved in a mortar using 15 ml of water, the aqueous solution was adjusted to pH 7.6 with concentrated ammonia solution, and then iodine (25.4 g; 0.1 mol) and, after 100 minutes, hydroxypropyl-β-cyclodextrin (100 g; 0.067 mol) were added to the solution. The suspension was continuously mixed with a pestle for about 1 h and allowed to dry until a solid product was obtained which could be easily reduced to a powder with a pestle. The percentage of available iodine (titrable with thiosulfate) in the iodophor thus obtained was found to be 12.3%.

[0145] Example 5. Preparation of HPβCD / I2

[0146] Hydroxypropyl-β-cyclodextrin (150 g; 0.1 mol) was dry mixed with molecular iodine (20.3 g; 0.08 mol) and then introduced into a rotary ball mill. The mixture was placed under the mechanical action of the mill, according to the set power, until the desired particle size was obtained at the end of the grinding. The percentage of available iodine (titrable with thiosulfate) in the iodophor product obtained was found to be 11.3%.

[0147] Example 5.1 Preparation of HPβCD / I2

[0148] Hydroxypropyl-β-cyclodextrin (150 g; 0.1 mol) powder was dry mixed with molecular iodine (25.4 g; 0.1 mol) previously crushed with a pestle in a mortar and then introduced into a closed glass container, which was heated at 60° C. for 10 h and the resulting product was then left in an open state until it reached room temperature. The percentage of available iodine (titrable with thiosulfate) in the iodophor product thus obtained was found to be 12.9%.

[0149] Example 6. Preparation of RMβCD / I3H

[0150] 20.2 g of a 57% aqueous solution of hydroiodic acid (equivalent to 11.5 g; 0.09 mol of hydroiodic acid) is introduced into 50 ml of ethanol, in which 22.8 g (0.09 mol) of iodine have previously been dissolved. The ethanol solution thus composed is poured into 160 g (0.12 mol) of methyl-β-cyclodextrin, the paste is homogenized in a mortar and pestle (if necessary, a few ml of ethanol or water are added to achieve a suitable consistency) until the paste is dry, and the almost dry powder product is introduced into a rotary mill in a 400 ml Teflon container. The rotor acceleration is 1 g, and the rotation speed of the container is set to 200 rpm. 20 mm zirconium oxide balls are used as grinding bodies. The mechanical process lasts for 40 minutes. The percentage of available iodine in the iodophor obtained is obtained to be 11.9%. The powder obtained is forced through a 0.038 mm sieve and then formulated.

[0151] Example 6.1 Preparation of RMβCD / I3H

[0152] 30.48 g (0.12 mol) of iodine and 160 g (0.12 mol) of methyl-β-cyclodextrin were mixed and homogenized lightly in a mortar with a pestle, the mixture was transferred to a sealed glass container with a screw cap and then heated at 60° C. for 8 h. After the cyclodextrin iodine complex thus obtained was allowed to cool in air, 26.9 g of a 57% aqueous solution of hydroiodic acid (equivalent to 15.3 g; 0.12 mol of hydroiodic acid) were added, and then water was evaporated by rotary evaporation at room temperature and a pressure of 100 mmHg. The percentage of available iodine in the iodophor thus obtained was found to be 13.2%. The powder obtained was forced through a 0.038 mm sieve and then formulated.

[0153] Example 7. Preparation of RMβCD / I3K

[0154] Methyl-β-cyclodextrin (131 g; 0.1 mol) and potassium iodide (12.5 g; 0.075 mol) were dry mixed with molecular iodine (19.0 g; 0.075 mol) and then introduced into a rotary ball mill. The mill was placed under mechanical action until the desired particle size was obtained, according to the set power, and at the end of the grinding the product was forced through a 0.038 mm sieve and then formulated. The percentage of available iodine (titrable with thiosulfate) was found to be 10.4%.

[0155] Example 7.1 Preparation of RMβCD / I3K

[0156] Methyl-β-cyclodextrin (131 g; 0.1 mol) and potassium iodide (12.5 g; 0.075 mol) were mixed in 25 ml of an ethanolic solution containing molecular iodine (19.0 g; 0.075 mol) and then introduced into a rotary ball mill. The mill was placed under mechanical action until the desired particle size was obtained, depending on the power setting. The percentage of available iodine (titrable with thiosulfate) was found to be 11.7%.

[0157] Example 8. Preparation of βCD / I3H

[0158] β-Cyclodextrin (113.5 g; 0.1 mol) is suspended in 35 ml of water. To this suspension is added ammonium formate (2.40 g; 0.037 mol) and the suspension is then adjusted to pH 7.5 with an ammonia solution. Iodine (28.4 g; 0.112 mol) is introduced into the suspension. The pasty suspension is placed under mechanical stirring for about 2 hours, until the foaming produced by the CO2 development ends, after which the solution is heated to 70° C., the solid is ground from time to time with a pestle until dry and a powder is obtained. The percentage of available iodine in the iodophor obtained is found to be 13.4%.

[0159] Example 9. Preparation of βCD / I3K

[0160] 25.4g iodine (0.1mol) and 19.9g potassium iodide (0.12mol) were dissolved in 45ml ethanol, and then the ethanol solution was poured on 113g of beta-cyclodextrin (0.1mol) previously placed in a porcelain mortar. The paste was manually squeezed and homogenized with a pestle until a powder was obtained. The product was allowed to air dry for 3h. The percentage of available iodine was obtained to be 15.6%. The product was prepared as above.

[0161] Example 10. Preparation of αCD / I3H

[0162] 16.7 g of a 57% aqueous solution of hydroiodic acid (corresponding to 9.5 g; 0.075 mol of hydroiodic acid) are introduced into 40 ml of ethanol, in which 19.0 g (0.075 mol) of iodine have previously been dissolved. The ethanol solution thus composed is poured onto α-cyclodextrin (97.3 g; 0.1 mol). The paste is homogenized in a mortar and pestle (if necessary, a few ml of ethanol or water are added to obtain the appropriate consistency of the paste) until a dry powder product is obtained. The percentage of available iodine in the iodophor thus obtained is found to be 14.9%.

[0163] Each of the above preparations can be used starting from any unsubstituted or substituted α, β, and γ-cyclodextrin.

[0164] Structure confirmation

[0165] According to the analysis (thermogravimetric, infrared and UV), the iodophor obtained in the above examples is a new inclusion structure.

[0166] method

[0167] Thermogravimetric analysis was performed using a TGA Q500 (TA Instruments, a division of Waters) using a platinum crucible, under a nitrogen atmosphere (flow rate 60 mL / min), in the temperature range of 50°C to 500°C, with a heating rate of 5°C per minute. 2 to 8 mg of sample were weighed for analysis. The weight loss percentage and the corresponding derivative were recorded as a function of temperature.

[0168] IR analysis was performed using a Perkin Elmer Spectrum 100 spectrometer (Perkin Elmer, Waltham, MA, USA) and reported as Fourier transform spectroscopy (FTIR). The samples were analyzed directly without pretreatment using a general ATR sampling system to obtain a wavelength range of 4000 to 600 cm -1 The spectrum with a resolution of 4.0 cm -1 .

[0169] UV analysis of the novel unreported iodine phors in water showed that for all inclusion complexes, there were typical triiodide ion absorption bands at 352 nm and typical iodine absorption bands between 450 and 550 nm.

[0170] By UV spectroscopy and / or thiosulfate titration, the determined amount of available iodine in the various iodophors is always what is expected from the stoichiometry used in the preparation. Similarly, from the aqueous phase containing any of the iodophors of the present patent application, an aliquot for subsequent extraction with cyclohexane is collected in a single container until the aqueous phase changes color to provide an organic phase containing all the molecular iodine I2 as expected from the stoichiometry of the preparation, this assessment being performed by UV spectroscopy at a wavelength of 525 nm (maximum absorption of molecular iodine in cyclohexane).

[0171] The figures show the thermograms and FTIR graphs of some of the compounds exemplified in the Examples.

[0172] Table 1 below shows data from thermogravimetric analysis.

[0173] Table 1

[0174]

[0175]

[0176] Table 2 below shows data evaluated using FTIR.

[0177] Table 2

[0178]

[0179]

[0180] Stability of solid iodine

[0181] The resulting powdered iodine product was placed in a low density polyethylene container at a temperature of 25°C and a relative humidity (RH) of 60%. The product was highly stable, as expected from thermogravimetric studies. After 24 months, the iodine content of all CD / I3K and CD / I3H products was 100% of the initial titer, and the CD / I2 complex was greater than 90% except for γCD / I2 which reached 82% of the initial iodine titer. The following table shows the control at the date of production (T0) and after 3 months (T3), 6 months (T6), 12 months (T12) and 24 months (T24).

[0182] Table 3 below shows the results of the solid iodine phor stability study.

[0183] Table 3

[0184]

[0185]

[0186] Stability of iodine tincture in aqueous solution

[0187] Iodine tincture was prepared in an aqueous solution of 0.025% available iodine (about 0.25% by weight of iodine tincture). The formulations were placed in 50 ml glass vials with polypropylene screw caps and Teflon septa and stored at a temperature of 25°C and a relative humidity (RH) of 60%. 1 ml was taken from different formulations at the time of analysis.

[0188] The table below shows the stability data for some iodine phors in 0.25% aqueous solutions.

[0189] Table 4.

[0190]

[0191]

[0192] Biocidal activity

[0193] Determination of antiviral activity (time kill assay)

[0194] Each virus suspension to be tested is replicated in the MRC-5 cell line to produce a high titer of each virus. After viral replication, the culture is frozen / thawed nearly 3 times to destroy the cells, and the cell fragments are separated by centrifugation (400g 15 minutes). For each virus strain, TCID50 / mL (tissue culture infection dose 50) is determined by titration on a plate reader, and used to inoculate three different test solutions: available iodine is 0.025% of the iodine tincture to be tested, a blank negative control, and a positive control composed of a blank containing an antiviral drug with a relative IC50 of the virus in question. Each virus strain is used to inoculate three test solutions, by adding 100 μL of each virus strain to a tube containing 900 μL of iodine tincture solution to be tested, 900 μL of blanks and 900 μL of positive controls (antiviral drugs prepared in blanks). Incubation time is: 5s, 10s, 30s, 1, 3, 6, 60min, 3, 6, 12 hours. After the determined contact time, the treated suspension containing the virus strain was neutralized with a sterile solution of 0.5% (w / w) sodium thiosulfate at a dilution of 1:10 (v / v). Methods Log titers in TCID50 / mL were calculated as described in paragraph C.3.2 of UNI EN 14476:2013+A2:2019(E). The iodine phorborate of the invention induces the following inhibition at an effective iodine concentration of 0.025: ≥3-Log10 after 5 seconds of exposure; ≥4-Log10 after 1 minute of exposure, and ≥5-Log10 after 6 hours of exposure.

[0195] Determination of antimicrobial activity (time kill assay)

[0196] Bacterial suspensions of each reference strain were prepared from 16-hour growth cultures and then diluted to ~1.5 x 10 8 CFU / ml was estimated by UV spectrophotometer using a standard turbidity of 0.5 McFarland units as reference. Three types of samples were inoculated for each bacterial strain: the iodine tincture to be tested with 0.025% available iodine, a blank negative control, and a positive control consisting of a blank containing the antibiotic at a concentration corresponding to the respective MIC of each microorganism evaluated. Approximately 7.5 x 10 6 CFU / ml to obtain an intermediate suspension of 5x10 5 Each bacterial suspension was used to inoculate three samples, and 100 μL of each bacterial suspension was added to three tubes containing 1.9 mL of the iodine to be tested, 1.9 mL of the blank preparation, and 1.9 mL of the positive control, respectively. The final concentration of each bacterial suspension was ~5x10 5CFU / mL. The dilution effect of the inoculum does not affect the concentration of the tested solution because it does not exceed 5% of the total final volume of the test. Three samples containing the inoculated bacterial suspension were incubated for the following times: 10, 20, 40s, 1, 2, 4, 8, 60min, 6 and 12h. After the set time, the suspension in the tube was diluted 1:10 (v / v) by withdrawing 100 μL, and a sterile 0.5% sodium thiosulfate solution with a final volume of 1000 μL was obtained. From this suspension, 100 μL was inoculated on an agar plate / medium, and the plate was then incubated at 37°C for 24-48 hours. The control of the inoculum applied by the time killing test was carried out as follows. From the last suspension of each bacterial strain used for colony count calculation, two 1:10 (v / v) dilutions were prepared in sterile saline and placed on agar / medium to verify the inoculum used for the test. Dilutions were made to have colony counts between 20-300 CFU / plate as intervals, but not less than 6. Colony counts were performed after the plates were incubated at 37°C for 24 hours. The iodine phorborate of the present invention induced an inhibition effect of ≥3-Log10 at exposures between 10s and 2 minutes, but most bacterial strains were inhibited within 40s.

[0197] Determination of antifungal activity (time kill assay)

[0198] Fungal suspensions of each reference strain were prepared from 5-7 day grown cultures and then diluted to ~1.5 x 10 6 CFU / ml was estimated by UV spectrophotometer using a standard turbidity of 0.5 McFarland units as reference. Each fungal strain was inoculated with three types of samples: the iodine tincture to be tested with 0.025% available iodine, a blank negative control, and a positive control consisting of a blank containing an antifungal agent at a concentration corresponding to the respective MIC of each microorganism evaluated. Each fungal suspension was used to inoculate three samples, and 100 μL of each bacterial suspension was added to three tubes containing 1.9 mL of the iodine tincture to be tested, 1.9 mL of the blank preparation, and 1.9 mL of the positive control, respectively. The final concentration of each fungal suspension was approximately 2x10 4 ÷1x10 5CFU / mL. The dilution effect of the inoculum does not affect the concentration of the tested solution, since it does not exceed 5% of the total final volume tested. The three samples containing the inoculated fungal suspension were incubated for the following times: 10, 20, 40 s, 1, 2, 4, 8, 60 min, 3, 6 and 12 h. After the set time, the suspension in the tube was diluted 1:10 (v / v) by withdrawing 100 μL and a sterile 0.5% sodium thiosulfate solution with a final volume of 1000 μL was obtained. From the latter, a suspension was prepared in sterile water by dilution 1:10 (v / v), from which 50 μL of each fungal strain was taken and plated on agar medium, and the plates were incubated at 35°C for 24-72 hours. According to ISO 21527-2:2008: Selection and counting of plates containing less than 150 colonies, the control of the inoculum applied for the time-killing test was carried out simultaneously with the test so as to have a colony count of ≤150 colonies. The plates were incubated at 35°C for 24-72 hours. Non-linearity in counts often occurs with dilution, i.e., a 10-fold dilution of a sample often does not translate into a 10-fold reduction in the number of colonies recovered. This is due to the breakage of the mycelium and the destruction of the spore mass during the dilution process, as well as competitive inhibition, particularly when large numbers of colonies are present on the plate. The iodophors of the present invention showed efficacy in reducing fungal growth, with a reduction of 99.999% after a 10-second exposure in most of the above-mentioned test strains.

[0199] From the above description, the advantages provided by the present invention will be immediately apparent to those skilled in the art.

[0200] In particular, it should be noted that the solid iodophor complexes described offer the possibility of having available stable powder compositions containing high concentrations of iodine from which stable aqueous solutions can be obtained; this is a great advantage over iodophors formulated directly in water.

[0201] Solid iodine phorbs are preferred over iodine phorbs in solution because they are easier to store, can be formulated in water or other solvents at the desired concentration, can be included in solid and semisolid matrices or used directly as a powder.

[0202] The invention further provides a process for preparing solid complexes CD / I2 between cyclodextrins and molecular iodine which has general validity and is not limited by the precipitation of these products in water.

[0203] The method of the present invention can also produce known complexes, but surprisingly, it can also produce a new class of stable powdered solid iodophors (CD / I3) composed of any cyclodextrin and triiodide ion. - ).

[0204] Since the biocidal activity depends on the free iodine obtained by the dissociation of the complex with the cyclodextrin, in the case of the iodophors of the present invention, the free iodine is provided by the dissociation equilibrium of the complex CD / I3K or CD / I3H or CD / I2, and the free iodine level increases linearly with the iodophor concentration, which has advantages over the technology using povidone iodine. In fact, in order to provide a stable solution, this technology needs to be formulated at a high concentration (usually 10%), at which the polyvinylpyrrolidone polymer aggregates and captures the iodine to provide a solution with only 2-4ppm of free iodine in a composition containing 15000pm of total iodine not used for biocidal activity. In the case of the present invention, on the contrary, the iodophor complex based on cyclodextrin does not aggregate. Therefore, for the same concentration, the iodophor complex of the present invention can provide a stable preparation with a significantly larger amount of free iodine.

Claims

1. A method for preparing a solid iodine phorbium complex comprising iodine and cyclodextrin, comprising the step of mixing molecular iodine and possibly a source of iodide ions with cyclodextrin.

2. The method according to the preceding claim, wherein: The iodine and the iodide ion source are added to the cyclodextrin separately.

3. The method according to claim 1 or 2, wherein: The cyclodextrin is a substituted cyclodextrin or an unsubstituted cyclodextrin or an unsubstituted α-cyclodextrin, β-cyclodextrin or γ-cyclodextrin.

4. A method according to any one of the preceding claims, wherein: The cyclodextrin is selected from the group consisting of α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin, hydroxypropyl-α-cyclodextrin, methyl-β-cyclodextrin, sulfobutyl ether-β-cyclodextrin, hydroxypropyl-γ-cyclodextrin, methyl-γ-cyclodextrin, sulfobutyl ether-γ-cyclodextrin, methyl-carboxy-thioether-γ-cyclodextrin.

5. A method according to any one of the preceding claims, wherein: The iodide ion source is represented by an iodide salt or hydroiodic acid (HI), possibly generated in situ from an iodide salt and a reducing agent selected from the group comprising carbonic acid, formic acid, oxalic acid or their ammonium salts or urea.

6. A method according to any one of the preceding claims, wherein: The mixing is carried out in a rotary or vibrating ball mill or in a mortar with a pestle.

7. The method according to any one of the preceding claims 1 to 6, wherein: The mixing is carried out in the absence of a solvent.

8. The method according to any one of the preceding claims 1 to 6, wherein: The mixing is performed in the presence of a solvent, wherein the solvent is selected from the group consisting of water, alcohol-water mixture, ethanol, isopropanol, tetrahydrofuran, ether, ethyl acetate, and hexane.

9. The method according to the preceding claim, wherein: The mixing is performed in the presence of a solvent amount of about 0.1-1.2 ml / g of solid mixture.

10. A method according to any one of the preceding claims, carried out by heating the mixture in a closed container to a temperature of about 40-120°C.

11. A method according to any one of the preceding claims, wherein: The molar ratio of cyclodextrin to molecular iodine and iodide ion is about 1:0.05 to about 1:2 mol / mol for cyclodextrin and molecular iodine, and preferably the ratio is between about 1:0.25 to about 1:1.

2.

12. A method according to any one of the preceding claims, wherein: The molar ratio of molecular iodine to iodide ion is from about 1:0 to about 1:4 mol / mol, and preferably the ratio is between about 1:0.25 to about 1:

2.

13. A method according to any one of the preceding claims, comprising a further grinding and / or micronising step.

14. A solid iodophor complex of the formula: CD / Ix, in, CD is a cyclodextrin selected from the group consisting of substituted cyclodextrins and unsubstituted cyclodextrins or unsubstituted α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin, x=2 and / or 3, wherein when x=2 then CD is not α-cyclodextrin, β-cyclodextrin, hydroxypropyl-α-cyclodextrin, methyl-β-cyclodextrin, obtained according to the method of any one of the preceding claims.

15. A solid iodine complex of the formula: CD / Ix, in, CD is a cyclodextrin selected from the group consisting of substituted cyclodextrins and unsubstituted cyclodextrins or unsubstituted α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin, x=2 or 3, wherein when x=2, CD is not: α-cyclodextrin, β-cyclodextrin, hydroxypropyl-α-cyclodextrin, methyl-β-cyclodextrin.

16. The solid iodine complex according to the preceding claim, wherein The cyclodextrin is selected from the group consisting of α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin, hydroxypropyl-α-cyclodextrin, methyl-β-cyclodextrin, sulfobutyl ether-β-cyclodextrin, hydroxypropyl-γ-cyclodextrin, methyl-γ-cyclodextrin, sulfobutyl ether-γ-cyclodextrin, methyl-carboxy-thioether-γ-cyclodextrin.

17. A preparation comprising one or more solid iodine phorbium complexes according to claim 14 in a concentration such that an available iodine solution of between 0.01 and 2% is obtained.

18. The solid iodine phorbium complex according to claim 14, 15 or 16 or the preparation according to claim 17 for medical use.

19. The solid iodine phorbium complex according to claim 14 or 15 or 16 or the preparation according to claim 17 for antiviral, antibacterial and antifungal medical use.

20. Use of the solid iodine phorbol complex according to claim 14, 15 or 16 in agriculture, plant quarantine, aquaculture and animal husbandry.